Heron Therapeutics Inc (NASDAQ:HRTX) traded at $2.22 at close of the session on Monday, March 10 and made a downward move of -7.11% on its previous day’s price.
Heron Therapeutics Inc has a market cap of $338.17 million and is expected to release its quarterly earnings report in April.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 37.08M, with a low of 35.25M and a high of 38.1M. The median projection represents growth squeezing down to 6.96% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 158.17M, or 9.62% up from figures reported last year.
On the other hand, looking at the outlook for the HRTX stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 25% Buy.
Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Heron Therapeutics Inc (HRTX) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 13.53% off its SMA20 and 24.80% from its 50-day simple moving average. The RSI (14) is pointing at 57.96 while the volatility over the past week is 10.82% and jumps to 9.02% over the past one month. The beta value is 1.38, while the average true range (ATR) is currently pointing at 0.19. The average price target for the stock over the next 12 months is $7, with the estimates having a low of $5 and a high of $9. These price ends are -125.23% and -305.41% off the current price level respectively, although investors could be excited at the prospect of a -215.32% if the HRTX share price touches on the median price of $7.
